Eli Lilly Terminates CVS Health in Strategic Pivot for Employee Benefits
Published on 11/12/2025 at 10:22 | Redaktion boerse-global.de
Pharmaceutical giant Eli Lilly has made a decisive move in its corporate benefits strategy, immediately dropping CVS Health as its prescription drug provider for employees. This significant shift follows CVS’s earlier decision to remove Eli Lilly’s blockbuster weight-loss injection from its formulary of covered medications, opting instead for a competing product. Beginning January 1, Rightway will assume responsibility for pharmaceutical services. This development underscores the intensely competitive landscape within the multi-billion dollar obesity medication sector, raising questions about Eli Lilly’s ability to maintain its market leadership position.
Against this backdrop of corporate maneuvering, Eli Lilly’s stock performance continues its remarkable ascent. On Tuesday, November 11, 2025, shares briefly approached the Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
